Juan Andres - 01 Jun 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
01 Jun 2021
Transactions value $
-$1,717,800
Form type
4
Date filed
03 Jun 2021, 16:43
Previous filing
27 May 2021
Next filing
09 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 01 Jun 2021 Direct F1
transaction MRNA Common Stock Sale -$920K -5K -100% $184.08 0 01 Jun 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 02 Jun 2021 Direct F1
transaction MRNA Common Stock Sale -$920K -5K -100% $183.90 0 02 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -0.97% $0.00 510K 01 Jun 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -0.98% $0.00 505K 02 Jun 2021 Common Stock 5K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.
F2 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer